Trelegy Ellipta and Lung Function Improvement
Help improve lung function for COPD patients with a once-daily single-inhaler Triple Therapy 2,7
Breathing Better: How single-inhaler Triple Therapy could help your patients with COPD from today
Over 50% of patients treated with COPD maintenance therapies, including ICS/LABA, continue to suffer from breathlessness4
TRELEGY Ellipta provides statistically superior lung function improvement vs.budesonide/formoterol2
TRELEGY Ellipta provides statistically superior lung function improvement vs.a LAMA/LABA (UMEC/VI)3
Statistically superior improvement in lung function vs. budesonide/formoterol2
Statistically superior improvement in lung function vs. a LAMA/LABA (UMEC/VI)3,6
Key trial design
Get started with Trelegy Ellipta
Footnotes
BD, twice daily; BUD, budesonide; CAT, COPD assessment test; CI, confidence interval; FEV1, forced expiratory volume in one second; FF, fluticasone furoate; FOR, formoterol; ICS, inhaled corticosteroid; LABA, long-acting ß2-agonist; LAMA, long-acting muscarinic antagonist; LS, least squares; OD, once daily; MCID, minimal clinically important difference; SGRQ, St George’s Respiratory Questionnaire; UMEC, umeclidinium; VI, vilanterol
TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA¹
References
- TRELEGY Ellipta SmPC. Available at https://www.medicines.ie. Accessed April 2024.
- Lipson DA et al. Am J Crit Care Med 2017; 196:438–446.
- Lipson DA et al. N Engl J Med 2018; 378:1671–1680.
- Rebordosa C et al. Pharmacoepidemiol Drug Saf 2019; 28:126–133, including supplementary material.
- Jones PW et al. Am J Respir Crit Care Med 2014; 189:250–255.
- GSK, Data on File. RF/TLY/0067/18. IMPACT Study: trough FEV1 data over 52 weeks.
- Tabberer M et al. Adv Ther 2018; 35:56–71.
Adverse events should be reported directly to the Health Products Regulatory Authority (HPRA) on their website: www.hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Trelegy is a registered trademark of the GlaxoSmithKline group of companies.
TRELEGY Ellipta was developed in collaboration with
Last Updated: April 2024 PM-IE-FVU-WCNT-240002